Featured Research

from universities, journals, and other organizations

Alzheimer's Drug Reverses Cognitive Decline Over 12 Month Period In Early Human Testing

Date:
July 18, 2008
Source:
Baylor College of Medicine
Summary:
A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a new study. Dimebon is the first drug tested for Alzheimer's disease that demonstrated continued improvement in patients over a 12 month period.

PET scan of Alzheimer's disease brain.
Credit: National Institute on Aging, NIH

A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a study conducted there, said an expert at Baylor College of Medicine in Houston. The findings are published in the journal The Lancet.

"More research is needed, but we are encouraged by the effect the drug Dimebon had on Alzheimer's patients" said Dr. Rachelle Doody, professor of neurology at BCM and lead author of the study.

In the study, the authors noted that Dimebon is the first drug for Alzheimer's disease that demonstrated continued improvement in patients over a 12 month period. Other approved drugs do not have this effect.

Half of the 183 patients in the Russian study received Dimebon; the other half were given a placebo or an inactive pill. Clinicians at the study sites then monitored the patients' progress over the next year on five different outcomes. All of those in the study had mild to moderate Alzheimer's disease.

"What we saw in the clinical trial is that people on the medication continued to improve over time," Doody said. "Those on placebo continued to decline."

Researchers believe the medication works by stabilizing mitochondria, the cellular components that produce energy, and possibly by inhibiting brain cell death. Researchers evaluated patients' thinking and memory ability, overall function, psychiatric and behavioral symptoms, and ability to perform daily activities.

"Usually at this point in a drug's development, we are happy to see improvement in one of the outcome measures," Doody said. "We saw improvement in all five."

Some participants complained of occasional dry mouth, but no one opted out of the study because of the side effects.

"As we continue research, we hope to replicate these results," Doody said. "My belief is that this drug will turn out to be useful for Alzheimer's disease, regardless of the stage of the disease."

Doody said this is only the first study looking into the effects of Dimebon on Alzheimer's disease. She also noted that it involved only a relatively small population from one specific region of the world. The ongoing Phase 3 study will include several international locations including the United States.

Other researchers who contributed to this study include: Dr. Svetlana I. Gavrilova, Russian Academy of Medical Sciences, Moscow, Russia; Dr. Mary Sano, Mount Sinai School of Medicine, New York City, NY; Dr. Ronald G. Thomas, University of California, San Diego, La Jolla, CA; Dr. Paul S. Aisen, formerly with Georgetown University School of Medicine, Washington, DC and now at the University of California, San Diego; ; Dr. Sergey O. Bachurin, Russian Academy of Sciences, Institute of Physiologically Active Compounds, Chernogolovka, Russia; Drs. Lynn Seely and David Hung, Medivation, Inc., San Francisco, CA.

Funding for this study came from Medivation, Inc., the company developing the drug worldwide. Doody is also a member of the Scientific and Clinical Advisory board for Medivation, Inc.


Story Source:

The above story is based on materials provided by Baylor College of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Dimebon for Alzheimer's disease. The Lancet, July 18, 2008 [link]

Cite This Page:

Baylor College of Medicine. "Alzheimer's Drug Reverses Cognitive Decline Over 12 Month Period In Early Human Testing." ScienceDaily. ScienceDaily, 18 July 2008. <www.sciencedaily.com/releases/2008/07/080717193029.htm>.
Baylor College of Medicine. (2008, July 18). Alzheimer's Drug Reverses Cognitive Decline Over 12 Month Period In Early Human Testing. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2008/07/080717193029.htm
Baylor College of Medicine. "Alzheimer's Drug Reverses Cognitive Decline Over 12 Month Period In Early Human Testing." ScienceDaily. www.sciencedaily.com/releases/2008/07/080717193029.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins